---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000039"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:00:07.889844+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iBio Q1 FY2026 revenue $0.1M; cash $49.6M; IBIO-610 half-life up to 100 days

## Summary
- Revenue $0.1M vs $0 prior year; R&D expenses $3.6M (up $2.3M YoY); G&A $2.5M (down $0.3M).
- Cash $49.6M as of Sept 30, 2025, expected to fund operations into Q4 FY2027.
- Closed $50M public offering; potential additional $50M from common warrant exercise for total up to $100M.
- IBIO-610 NHP data shows predicted human half-life up to 100 days, enabling potential twice-yearly dosing.
- Regained Nasdaq compliance on Nov 4, 2025.

## SEC filing metadata
- accession: 0001420720-25-000039
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000039/0001420720-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000039/ibio-20251112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000039
- JSON: https://secwatch.observer/filing/0001420720-25-000039.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.